comparemela.com

Latest Breaking News On - Astrazeneca enhertu - Page 2 : comparemela.com

GSK adds to ADC dealmaking with second Chinese biotech pact

BioPharma

United statesSeagen adcetrisAstrazeneca enhertuEli lillyBristol myersHansoh pharmaBristol myers squibbMerck coAmerican society of clinical oncologyDive briefChina based hansoh pharmaAmerican societyClinical oncologySichuan biokin pharmaceutical

Bristol Myers pays $100M for a different kind of ADC

BioPharma

South koreaTaejon gwangyoksiUnited statesDaiichi sankyoSeagen adcetrisJoo leeAstrazeneca enhertuBristol myersBristol myers squibbAmerican society of hematologyDrug administrationDive briefMyers squibbOrum therapeuticsAmerican societySung joo lee

GlobalData : Novartis eyes HR+/HER2- early breast cancer market with NATALEE trial success, says GlobalData -November 01, 2023 at 10:35 am EDT

01 Nov, 2023 Novartis eyes HR+/HER2- early breast cancer market with NATALEE trial success, says GlobalData Share Print.

Thomas walesAstrazeneca enhertuEli lily verzenioNovarti kisqaliNational comprehensive cancer networkEuropean medical society of oncologyEuropean medical societyEli lilyOncology analyst

Merck cancer drug deal caps pharma investment influx into ADC field

BioPharma

Eli lillyDaiichi sankyoAstrazeneca enhertuRoche kadcylaMablink bioscienceSeagen adcetrisEuropean society of medical oncologyBristol myers squibbMerck coDaiichi sankyo fridayEuropean societyMedical oncologyMyers squibb

Jefferies upgrades this pharma stock, citing overlooked blockbuster drug opportunities

Analyst Peter Welford said that Astrazeneca's R&D assets outside the oncology pipeline can offer "significant upside optionality."

Pascal soriotDaiichi sankyoAstrazeneca enhertuPeter welfordAnalyst peter welfordBreaking news marketsStock marketsInvestment strategyAstrazeneca plcBusiness news

vimarsana © 2020. All Rights Reserved.